Recombinant Human Klotho beta Protein, CF

When Recombinant Human FGF-21 (2539-FG) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human Klotho beta His-tag (Catalog # 5889-KB) binds with an ED50 of 2.5-20 ng/mL.

1 μg/lane of Recombinant Human Klotho beta was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 126 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Klotho beta Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human FGF-21 (Catalog # 2539-FG) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human Klotho beta His-tag (Catalog # 5889-KB) binds with an ED₅₀ of 2.5-20 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human Klotho beta protein
  Phe53-Leu997, with a C-terminal 10-His tag
• Accession #: Q86Z14
• N-terminal Sequence: Phe53
• Protein/Peptide Type: Recombinant Proteins
• Gene: KLB
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 110 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 113 - 125 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in PBS, Glycerol and EDTA.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Klotho beta Protein, CF

• betaKlotho
• beta-klotho
• BKL
• KLB
• klotho beta like
• Klotho beta
• klotho beta-like protein
• MGC142213

Background

Klotho beta , a divergent structural member of the glycosidase I superfamily, is expressed primarily in the liver and pancreas, with lower expression in adipose tissue (1, 2). Like Klotho, Klotho beta facilitates binding between FGF19 subfamily members and their receptors via formation of a ternary complex (3). The Klotho beta mediated interaction of human FGF19 (mouse FGF15) with FGF Receptor 4 in the liver negatively regulates bile acid synthesis by controlling the secretion of two key bile acid synthase genes, cholesterol 7-alpha hydroxylase (Cyp7a1) and sterol 12-alpha hydroxylase (Cyp8b1) (2-5). Klotho beta is also a cofactor for the interaction of FGF21 with FGF Receptor 1c in adipocytes, which allows FGF21 to stimulate GLUT1 expression, upregulating adipocyte insulin-dependent glucose uptake (2-4, 6). The 1043 amino acid (aa) type I transmembrane protein is composed of a 51 aa signal sequence, a 943 aa extracellular domain (ECD) containing two glycosidase-like regions, a 21 aa transmembrane domain, and 28 aa intracellular tail. Since Klotho-related proteins lack critical active site Glu residues present in beta -glycosidases, it was initially unclear whether they were functional enzymes (1, 7). However, glucuronidase activity has since been demonstrated for Klotho, indicating that physiologically relevant enzymatic activity for Klotho beta is also possible (8). The extracellular domain shares 79%, 87%, 87% and 67% identity with mouse, equine, canine and rat Klotho beta , respectively. The low identity with rat reflects aa discordance within rodent ECD.

1. Mian, I. S. (1998) Blood Cells Mol. Dis. 24:83.
2. Kurosu, H. and M. Kuro-o (2009) Mol. Cell. Endocrinol. 299:72.
3. Ito, S. et al. (2005) J. Clin. Invest. 115:2202.
4. Kurosu, H. et al. (2007) J. Biol. Chem. 282:26687.
5. Lin, B. C. et al. (2007) J. Biol. Chem. 282:27277.
6. Ogawa, Y. et al. (2007) Proc. Natl. Acad. Sci USA 104:7432.
7. Chang, Q. et al. (2005) Science 310:490.
8. Goetz, R. et al. (2007) Mol. Cell. Biol. 27:3417.

Publications for Klotho beta (5889-KB)(7)

Publications using 5889-KB

• YE Jung, KW Lee, JH Cho, DW Bae, BG Jeong, YJ Jung, SB Park, YJ An, K Kim, GS Lee, LW Kang, JH Moon, JH Lee, EK Kim, HS Yim, SS Cha Heating-mediated purification of active FGF21 and structure-based design of its variant with enhanced potency Scientific Reports, 2023-01-18;13(1):1005. 2023-01-18 [PMID: 36653390] (SPR, Human)
• C Yanucil, D Kentrup, X Li, A Grabner, K Schramm, EC Martinez, J Li, I Campos, B Czaya, K Heitman, D Westbrook, AR Wende, A Sloan, JM Roche, A Fornoni, MS Kapiloff, C Faul FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes Scientific Reports, 2022-05-05;12(1):7326. 2022-05-05 [PMID: 35513431] (Bioassay, Human)
• J Niu, J Zhao, J Wu, G Qiao, J Gu, C Zhou, Q Li, L Ying, D Wang, H Lin, X Li, M Mohammadi, Z Huang Curtailing FGF19&#039;s mitogenicity by suppressing its receptor dimerization ability Proc Natl Acad Sci U S A, 2020-11-03;0(0):. 2020-11-03 [PMID: 33144503] (SPR, Human)
• F Li, X Li, Z Li, W Ji, S Lu, W Xia betaKlotho is identified as a target for theranostics in non-small cell lung cancer Theranostics, 2019-10-12;9(25):7474-7489. 2019-10-12 [PMID: 31695781] (Cell Culture, Human)
• A Agrawal, S Parlee, D Perez-Tilv, P Li, J Pan, PA Mroz, AM Kruse Hans, B Andersen, B Finan, A Kharitonen, RD DiMarchi Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity Mol Metab, 2018-05-11;13(0):45-55. 2018-05-11 [PMID: 29789271] (Bioassay, Human)
• Gutknecht M, Geiger J, Joas S, Dorfel D, Salih H, Muller M, Grunebach F, Rittig S The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. Cell Commun Signal, 2015-03-24;13(0):19. 2015-03-24 [PMID: 25889792] (Control, Human)
• Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human)

Bioinformatics

• Gene Symbol: KLB
• Uniprot:
  • Q86Z14()